Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
CH0106213793
Wed, 17.04.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, April 17, 2024
Spexis announces extension of moratorium, receipt of an additional payment related to the sale of a preclinical antibiotics program and reversion of the lonodelestat license from Santhera
The Western District Court of the Canton Basel-Landschaft has granted Spexis [ … ]
Thu, 08.02.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, February 8, 2024
Spexis announces closing of sale of preclinical antibiotics program to Basilea
Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains
Transaction is part of S [ … ]
Mon, 15.01.2024
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, January 15, 2024
Spexis announces sale of preclinical antibiotics program to Basilea
Basilea to pay up to CHF 2 million for a preclinical program with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains
Preclinical studies demonstrated ba [ … ]
Tue, 05.12.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Spexis is Granted Debt-Restructuring Moratorium
Allschwil, Switzerland, December 5, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it has been formally granted moratorium status (Nachlassstu [ … ]
Wed, 29.11.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Spexis Provides Update Regarding Debt-Restructuring Moratorium
Allschwil, Switzerland, November 29, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that it is in discussions with SPRIM Global [ … ]
Wed, 08.11.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, November 8, 2023
Spexis to file an application for a debt-restructuring moratorium
Spexis AG (SIX: SPEX) is in the process of filing an application for a debt-restructuring moratorium with the Western District Court of the Canton Basel-Landschaft.
As previously reported in [ … ]
Wed, 01.11.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Spexis Announces Changes to the Executive Committee
Allschwil, Switzerland, November 1, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced that Hernan Levett, currently Chief Financial Officer [ … ]
Fri, 29.09.2023
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR
Spexis provides business update and announces financial results for the first half of 2023
Balixafortide, a potent CXCR4 inhibitor, to be evaluated for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Spexis closed capital commitments totaling USD $7.5 million supporting Phase 3 Coli [ … ]
Tue, 15.08.2023
Spexis AG
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studies
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, August 15, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, today announced a capit [ … ]
Fri, 30.06.2023
Spexis AG
Spexis announces engagement with Maxim Group LLC as M&A advisor to support evaluation of strategic transactions
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland, June 30, 2023
Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it has engaged Maxim [ … ]